Shanghai Henlius Biotech, Inc. (HKG:2696)

Market Cap	30.37B -21.9%
Revenue (ttm)	8.58B +28.2%
Net Income	1.00B +5.2%
EPS	1.82 +4.2%
Shares Out	545.26M
PE Ratio	30.54
Forward PE	29.59
Dividend	n/a
Ex-Dividend Date	n/a

Volume	913,000
Open	56.10
Previous Close	55.70
Day's Range	55.65 - 59.00
52-Week Range	50.25 - 87.10
Beta	0.51
Analysts	Strong Buy
Price Target	102.15 (+74.17%)
Earnings Date	Aug 21, 2026

About Shanghai Henlius Biotech

Shanghai Henlius Biotech, Inc. engages in the research and development of biologic medicines with a focus on oncology, autoimmune diseases, and ophthalmic diseases. It offers HANLIKANG, a rituximab injection for treating active glomerulonephritis; HANQUYOU, a trastuzumab injection to treat breast and metastatic breast, and gastric cancer; HANDAYUAN, an adalimumab injection for the treatment of rheumatoid arthritis, ankylosing spondylitis, psoriasis, uveitis, polyarticular juvenile idiopathic arthritis, pediatric plaque psoriasis, Crohn’s diseas...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2010
• Employees: 4,082
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 2696

Financial Performance

In 2025, Shanghai Henlius Biotech's revenue was 6.67 billion, an increase of 16.46% compared to the previous year's 5.72 billion. Earnings were 827.04 million, an increase of 0.80%.

Financial numbers in CNY

Analyst Summary

According to 8 analysts, the average rating for 2696 stock is "Strong Buy." The 12-month stock price target is $102.15, which is an increase of 74.17% from the latest price.

Price Target

$102.15

(74.17% upside)

Analyst Consensus: Strong Buy

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Sep 30, 2026

Data Sources Report a data error